MCID: MLG074
MIFTS: 54

Malignant Mesenchymoma

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Malignant Mesenchymoma

MalaCards integrated aliases for Malignant Mesenchymoma:

Name: Malignant Mesenchymoma 12 53 15
Malignant Mesenchymal Tumor 53 44 73
Rat Malignant Renal Mesenchymal Tumor 73
Mesenchymoma, Malignant 12
Sarcoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5758
MeSH 44 C535700
NCIt 50 C4268
SNOMED-CT 68 89623007

Summaries for Malignant Mesenchymoma

MalaCards based summary : Malignant Mesenchymoma, also known as malignant mesenchymal tumor, is related to mesenchymoma and gallbladder sarcoma. An important gene associated with Malignant Mesenchymoma is MB (Myoglobin), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Doxorubicin and Ritonavir have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Malignant Mesenchymoma

Diseases in the Mesenchymoma family:

Benign Mesenchymoma Malignant Mesenchymoma
Adult Malignant Mesenchymoma

Diseases related to Malignant Mesenchymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 mesenchymoma 32.2 DES MB MDM2 MYOD1
2 gallbladder sarcoma 31.7 DES KIT MYOD1 MYOG
3 conventional central osteosarcoma 30.4 EWSR1 MDM2
4 cystic nephroma 30.3 DES KIT WT1
5 suppressor of tumorigenicity 3 29.9 CDKN1A FHIT TP53
6 liposarcoma 29.6 CDK4 DES EWSR1 MB MDM2 TP53
7 sarcoma 29.0 EWSR1 KIT SSX2B TP53
8 rhabdomyosarcoma 27.9 CDK4 DES EWSR1 MB MDM2 MYOD1
9 leiomyosarcoma 27.6 CDK4 DES KIT MB MDM2 MYOG
10 childhood malignant mesenchymoma 12.1
11 adult malignant mesenchymoma 12.1
12 prostate embryonal rhabdomyosarcoma 10.9 KIT MYOD1
13 giant cell myocarditis 10.9 DES MB
14 ovarian fibrothecoma 10.9 DES KIT
15 malignant triton tumor 10.9 DES MB
16 botryoid rhabdomyosarcoma 10.9 DES MB MYOD1
17 spindle cell rhabdomyosarcoma 10.8 DES MB MYOD1
18 cervical polyp 10.8 DES MYOD1
19 adult mesoblastic nephroma 10.8 ETV6 NTRK3
20 alveolar soft part sarcoma 10.7 DES MB MYOD1
21 spindle cell lipoma 10.7 CDK4 DES MDM2
22 mixed liposarcoma 10.7 CDK4 MB MDM2
23 spindle cell sarcoma 10.7 DES MDM2 NTRK3
24 myofibroma 10.7 DES ETV6 MB
25 ischemic fasciitis 10.7 CDK4 DES MDM2
26 extraosseous osteosarcoma 10.7 CDK4 GALNT3 MDM2
27 zika virus infection 10.7 MDM2 TP53
28 lipomatosis, multiple 10.7 CDK4 DES MDM2
29 infiltrating angiolipoma 10.7 CDK4 MDM2
30 congenital fibrosarcoma 10.6 DES ETV6 NTRK3
31 pediatric fibrosarcoma 10.6 ETV6 NTRK3
32 meninges sarcoma 10.6 MB TP53
33 cutaneous ganglioneuroma 10.6 KIT NCAM1
34 sclerosing liposarcoma 10.6 MB MDM2 TP53
35 sarcomatoid squamous cell skin carcinoma 10.6 KIT MB TP53
36 testicular gonadoblastoma 10.6 KIT WT1
37 mesenchymal cell neoplasm 10.5 EWSR1 KIT MYOD1
38 myxosarcoma 10.5 MB MDM2 TP53
39 breast secretory carcinoma 10.5 CDK4 ETV6 NTRK3
40 bone osteosarcoma 10.5 CDK4 EWSR1 MDM2
41 malignant fibroxanthoma 10.5 CDK4 DES MDM2 MYOD1
42 deep leiomyoma 10.5 CALD1 KIT
43 mixed cell type cancer 10.5 KIT MB TP53
44 ring chromosome 7 10.5 CDK4 MDM2 TP53
45 orbit rhabdomyosarcoma 10.5 MB MYOG
46 fallopian tube carcinosarcoma 10.5 NCAM1 WT1
47 ewing's family of tumors 10.5 CDK4 EWSR1 KIT
48 periosteal osteogenic sarcoma 10.5 CDK4 MDM2 TP53
49 myositis 10.4 MB MYOD1 NCAM1
50 dermatofibrosarcoma protuberans 10.4 DES KIT TP53

Graphical network of the top 20 diseases related to Malignant Mesenchymoma:



Diseases related to Malignant Mesenchymoma

Symptoms & Phenotypes for Malignant Mesenchymoma

GenomeRNAi Phenotypes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.51 SSX2B WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.51 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.51 EWSR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.51 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.51 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.51 NTRK3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.51 EWSR1 NTRK3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.51 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.51 EWSR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.51 SSX2B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.51 EWSR1 NTRK3 KIT WT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.51 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.51 EWSR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.51 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.51 EWSR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.51 SSX2B WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.51 WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.51 NTRK3 KIT SSX2B WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.51 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.51 NTRK3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.51 KIT EWSR1 NTRK3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.51 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.51 SSX2B WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.51 EWSR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.51 SSX2B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.51 EWSR1 SSX2B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.51 KIT NTRK3 WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.51 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.51 KIT EWSR1
30 Reduced mammosphere formation GR00396-S 9.17 CDK4 DES ETV6 MDM2 NCAM1 GALNT3

MGI Mouse Phenotypes related to Malignant Mesenchymoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 UCHL1 NTRK3 WT1 TP53 CDK4 DES
2 growth/size/body region MP:0005378 10.36 TP53 MYOG UCHL1 NTRK3 PNLIP WT1
3 homeostasis/metabolism MP:0005376 10.35 UCHL1 PNLIP WT1 TP53 DES CDK4
4 cellular MP:0005384 10.29 TP53 NCAM1 WT1 CDKN1A DES CDK4
5 mortality/aging MP:0010768 10.28 TP53 MYOG NCAM1 UCHL1 NTRK3 WT1
6 digestive/alimentary MP:0005381 10.24 UCHL1 PNLIP TP53 CDK4 ETV6 CDKN1A
7 hematopoietic system MP:0005397 10.24 TP53 UCHL1 WT1 CDK4 ETV6 FHIT
8 embryo MP:0005380 10.18 WT1 TP53 MYOG CDK4 ETV6 CDKN1A
9 integument MP:0010771 10.16 TP53 MYOG UCHL1 CDK4 ETV6 FHIT
10 muscle MP:0005369 10.11 WT1 TP53 CDK4 DES CDKN1A GALNT3
11 liver/biliary system MP:0005370 10.03 WT1 TP53 UCHL1 PNLIP CDK4 CDKN1A
12 neoplasm MP:0002006 9.97 WT1 TP53 CDK4 ETV6 CDKN1A FHIT
13 no phenotypic analysis MP:0003012 9.91 TP53 MYOG NTRK3 WT1 ETV6 CDKN1A
14 normal MP:0002873 9.81 TP53 MYOG NTRK3 WT1 CDK4 ETV6
15 renal/urinary system MP:0005367 9.56 WT1 TP53 UCHL1 CDK4 CDKN1A GALNT3
16 respiratory system MP:0005388 9.28 WT1 TP53 MYOG UCHL1 NTRK3 CDKN1A

Drugs & Therapeutics for Malignant Mesenchymoma

Drugs for Malignant Mesenchymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 609)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
5
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
6
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
7
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
8
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 772 46507594
10
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
11
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
12
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
13
Aspirin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-78-2 2244
14
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
15
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
16
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
17
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
18
Enoxaparin Approved Phase 4,Not Applicable 9005-49-6 772
19
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
20
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
31 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
37 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
38 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
39 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50
Tenofovir Phase 4,Phase 3,Not Applicable 147127-20-6 464205

Interventional clinical trials:

(show top 50) (show all 1792)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
4 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
5 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
6 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
7 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
8 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
9 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Recruiting NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
10 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
11 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
12 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
13 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
15 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
16 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
17 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
18 Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma Unknown status NCT02672527 Phase 3 Trabectedin;Dexamethasone
19 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
20 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
21 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
22 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
23 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
24 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
25 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
26 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
27 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
28 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
29 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
30 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
31 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
32 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
33 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
34 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
35 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
36 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
37 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
38 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
39 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
40 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
41 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
42 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
43 Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Completed NCT00870701 Phase 3
44 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
45 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
46 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
47 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
48 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
49 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
50 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir

Search NIH Clinical Center for Malignant Mesenchymoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: malignant mesenchymal tumor

Genetic Tests for Malignant Mesenchymoma

Anatomical Context for Malignant Mesenchymoma

MalaCards organs/tissues related to Malignant Mesenchymoma:

41
Bone, Lung, T Cells, Uterus, Brain, Testes, Kidney

Publications for Malignant Mesenchymoma

Articles related to Malignant Mesenchymoma:

(show top 50) (show all 146)
# Title Authors Year
1
Primary malignant mesenchymoma of bladder: Case report and review of the literature. ( 28796040 )
2017
2
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors. ( 28832074 )
2017
3
Malignant mesenchymal tumors of the uterus - time to advocate a genetic classification. ( 27602604 )
2016
4
Critical reappraisal of primary osseous composite sarcoma (malignant mesenchymoma) - analysis of four cases and literature review. ( 27102568 )
2016
5
Pulsed radiofrequency treatment of piriformis syndrome in a pregnant patient with malignant mesenchymal tumor. ( 28111733 )
2016
6
Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: Lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. ( 27459057 )
2016
7
Malignant mesenchymal tumor of male breast: primary chondrosarcoma. ( 25821574 )
2015
8
Malignant mesenchymal tumor of the sacrum. ( 26022672 )
2015
9
Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. ( 25132008 )
2014
10
The treatment of paravertebral malignant mesenchymal tumor pain with cryoablation. ( 25037025 )
2014
11
Diagnosis and treatment considerations in a case of malignant mesenchymoma in an African fur seal (Arctocephalus pusillus). ( 23805568 )
2013
12
Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. ( 22154650 )
2012
13
Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma. ( 22833086 )
2012
14
Malignant mesenchymoma of the heart base in a dog with infiltration of the pericardium and metastasis to the lung. ( 22516086 )
2012
15
Combined cutaneous sarcoma: pleomorphic liposarcoma and conventional osteosarcoma-the so-called malignant mesenchymoma. ( 23082265 )
2012
16
Malignant mesenchymoma in the nasal cavity of a bull. ( 21306728 )
2011
17
Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group. ( 21495161 )
2011
18
Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee. ( 20473932 )
2011
19
Malignant mesenchymal tumor with leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, and osteosarcoma differentiation: case report and literature review. ( 21496258 )
2011
20
An intra-abdominal malignant mesenchymoma associated with nonabsorbable sutures in a ferret (Mustela putorius furo). ( 20224105 )
2010
21
Malignant mesenchymoma surrounding the esophageal hiatus. ( 20103193 )
2010
22
Malignant mesenchymoma of the thyroid: case report and literature review. ( 20572598 )
2010
23
A primary hepatic malignant mesenchymal tumor with myofibrogenic differentiation in a B6C3F1 mouse. ( 19332665 )
2009
24
Malignant Mesenchymal Tumor of the Breast: Primary Chondrosarcoma. ( 20847886 )
2009
25
Brachial plexus neuroma mimicking local recurrence of malignant mesenchymal tumor after forequarter amputation. ( 19292195 )
2008
26
Surgical case of giant malignant mesenchymoma in the posterior mediastinum that recurred in the bilateral mediastinum. ( 18781043 )
2008
27
Uterine malignant mesenchymoma, arising in a leiomyoma, with pulmonary metastases. ( 17257144 )
2007
28
Left atrial malignant mesenchymoma--emergency resection and mitral replacement. ( 17664193 )
2007
29
Intermandibular malignant mesenchymoma in a crossbreed dog. ( 16961475 )
2006
30
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. ( 15994146 )
2005
31
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. ( 15728225 )
2005
32
Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature. ( 15601312 )
2004
33
Malignant mesenchymal tumor arising from cherubism: a case report. ( 15170291 )
2004
34
Malignant mesenchymoma arising from a uterine leiomyoma in the menopause. ( 15581987 )
2004
35
Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. ( 15792374 )
2004
36
Malignant mesenchymoma of the orbit: case report and review of the literature. ( 12578773 )
2003
37
Severe and prolonged hypoglycemia triggered by long-acting octreotide in a patient with malignant mesenchymal tumor: case report. ( 12678421 )
2003
38
Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. ( 12792727 )
2003
39
Post-transfusion acute graft versus host disease in a 17-year-old girl with a malignant mesenchymal tumor--report of a case. ( 15055161 )
2003
40
Malignant mesenchymoma of the pleura. ( 17670075 )
2003
41
Retroperitoneal malignant mesenchymoma: a case of mesenchymal mixed tumor with osteosarcoma, leiomyosarcoma, liposarcoma and fibrosarcoma. ( 12514345 )
2002
42
Malignant mesenchymoma of the uterus, arising in a leiomyoma. ( 11903599 )
2002
43
Radical resection of a malignant mesenchymoma with hypogastric artery transposition. ( 12210036 )
2002
44
Primary malignant mesenchymoma of the heart. ( 11788281 )
2002
45
Malignant mesenchymoma of the lower leg. ( 11684725 )
2001
46
Giant malignant mesenchymoma of the spermatic cord with bidirectional differentiation. ( 11441285 )
2001
47
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions. ( 11605037 )
2001
48
Retroperitoneal malignant mesenchymoma: imaging findings in five cases. ( 9933683 )
1999
49
Ring chromosomes in a malignant mesenchymoma. ( 10087943 )
1999
50
Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog. ( 9657162 )
1998

Variations for Malignant Mesenchymoma

Expression for Malignant Mesenchymoma

Search GEO for disease gene expression data for Malignant Mesenchymoma.

Pathways for Malignant Mesenchymoma

Pathways related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.79 CDK4 CDKN1A KIT MDM2 TP53
2 12.77 CDK4 CDKN1A KIT MDM2 TP53
3
Show member pathways
12.67 CDK4 CDKN1A FHIT MDM2 TP53
4
Show member pathways
12.6 CDK4 CDKN1A MDM2 TP53 UCHL1
5
Show member pathways
12.29 CDK4 CDKN1A MDM2 TP53
6 12.27 CDK4 CDKN1A MDM2 TP53
7 12.17 CDK4 CDKN1A MDM2 TP53
8
Show member pathways
12.13 CDK4 CDKN1A MDM2 TP53
9 12.03 CDK4 CDKN1A MDM2 TP53
10 11.87 CDK4 CDKN1A MDM2 NTRK3 TP53
11 11.8 CDK4 CDKN1A MDM2 TP53
12
Show member pathways
11.76 CDKN1A MDM2 TP53
13 11.72 CDKN1A MDM2 TP53
14 11.7 CDKN1A KIT MYOD1
15 11.7 CDK4 CDKN1A FHIT TP53
16 11.68 CDK4 CDKN1A MYOD1
17 11.64 CDKN1A MDM2 TP53
18 11.61 CDK4 CDKN1A MDM2 TP53
19 11.56 KIT NTRK3 TP53
20 11.47 CDKN1A MDM2 MYOD1
21 11.44 CDKN1A ETV6 EWSR1 MDM2 SSX2B TP53
22 11.42 CDKN1A TP53 UCHL1
23 11.42 CDK4 CDKN1A MDM2 TP53
24 11.28 CDKN1A MYOD1 TP53
25 11.18 CDK4 CDKN1A TP53
26 11.16 CDK4 MDM2 TP53
27 11.12 CDK4 CDKN1A MDM2 TP53
28
Show member pathways
10.92 CDKN1A MDM2 TP53
29 10.9 CDK4 CDKN1A MDM2 TP53
30 10.72 CDKN1A TP53
31
Show member pathways
10.49 CDKN1A TP53

GO Terms for Malignant Mesenchymoma

Cellular components related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.77 CALD1 CDK4 CDKN1A DES ETV6 FHIT
2 nucleolus GO:0005730 9.17 CDK4 CDKN1A ETV6 EWSR1 MDM2 TP53

Biological processes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.73 MB MDM2 NTRK3 WT1
2 negative regulation of apoptotic process GO:0043066 9.63 CDKN1A KIT MDM2 NTRK3 TP53 WT1
3 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.54 CDKN1A MDM2 TP53
4 response to corticosterone GO:0051412 9.51 CDKN1A NTRK3
5 response to hyperoxia GO:0055093 9.49 CDK4 CDKN1A
6 replicative senescence GO:0090399 9.48 CDKN1A TP53
7 myotube differentiation GO:0014902 9.46 MYOD1 MYOG
8 positive regulation of skeletal muscle fiber development GO:0048743 9.4 MYOD1 MYOG
9 muscle cell fate commitment GO:0042693 9.32 MYOD1 MYOG
10 signal transduction by p53 class mediator GO:0072331 9.26 CDKN1A TP53
11 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
12 cellular response to gamma radiation GO:0071480 8.8 CDKN1A MDM2 TP53

Molecular functions related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 CALD1 CDK4 CDKN1A DES ETV6 EWSR1
2 p53 binding GO:0002039 9.33 MDM2 NTRK3 TP53
3 ubiquitin protein ligase binding GO:0031625 9.1 CDKN1A FHIT MDM2 MYOD1 TP53 UCHL1

Sources for Malignant Mesenchymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....